RDIF: Efficacy of Russia’s Sputnik V vaccine stands at 92%

MOSCOW, Nov 11 (PRIME) -- Interim analysis of the third stage clinical trials of Russia’s Sputnik V anti-coronavirus vaccine showed its efficiency at 92%, the Russian Direct Investment Fund (RDIF) said in a statement published on the vaccine’s Twitter page on Wednesday.

“The Sputnik V vaccine efficacy amounted to 92% – calculation based on 20 confirmed COVID-19 cases split between the vaccinated individuals and those who received a placebo,” the RDIF said, adding that the efficacy was demonstrated on the basis of the first interim analysis obtained 21 days after the first injection.

“Currently 40,000 volunteers are taking part in double-blind, randomized, placebo-controlled Phase III of clinical trials, of which over 20,000 have been vaccinated with the 1st dose of the vaccine and more than 16,000 – with both the 1st and 2nd doses of the vaccine.”

The people who received the vaccine suffered no unexpected adverse events during the trials, the fund said.

“The interim research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals. Following completion of Phase III clinical trials Gamaleya Center will provide access to a full clinical trial report,” the RDIF said.

End %%md/jst%%